Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JALSG APL212 post-remission therapy study in newly diagnosed adult acute promyelocytic leukemia
jRCTs041180100Phase 2Completed
- Sponsor
- JALSG Supportive Organization
- Start
- Aug 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide, gemtuzumab ozogamicin, tretinoin, tamibarotene, daunorubicin and 1 more in Acute promyelocytic leukaemia (APL), sponsored by JALSG Supportive Organization. Primary endpoint: 3-year event-free survival. Started Aug 2012; status: completed.
02
Drugs
arsenic trioxidegemtuzumab ozogamicintretinointamibarotenedaunorubicin
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on jRCTs041180100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180100.